CClinicalTrials.gg
CompletedNCT06680713EASYUpdated Nov 8, 2024

Single Maximal Exercise Session and the Metabolic Response of Physically Inactive Young Adults (EASY-Study)

An interventional study of Exercise in Physical Deconditioning, sponsored by Sergio Martinez-Huenchullan. Completed at 1 site in Chile. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Sergio Martinez-Huenchullan · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2024, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn how the metabolic parameters of physically inactive young adults respond to a progressive exercise testing. The main questions it aims to answer are:

Does a progressive exercise test induce metabolic adaptations that differ from a normal or physiologic status? Does the changes in circulating insulin might indicate metabolic dysfunctions in physically inactive young adults? Researchers will compare the metabolic status at baseline (rest) and the responses immediately after the finalization of a progressive exercise test until fatigue by collecting blood and urine samples before and after the exercise testing.

Participants will:

Undergo a progressive exercise test on a cycle ergometer where vital signs such as heart rate, blood pressure, rating of perceived effort, pulse and muscle oximetry will be recorded during the test.

Visit the laboratory once where all procedure will be conducted there. Stay in touch for the following week in case some exercise-related symptoms develops.

Read the detailed description

Design: This is a quasi-experimental study comparing pre-and post-intervention. The research question investigates the influence of changes in blood lactate influenced by exercise on the plasma concentration of FGF21 in physically inactive people. This project has the approval of the Scientific Ethics Committee of the Valdivia Health Service (Ord. 222/2022) and has Biosafety certification by the Institutional Biosafety Committee of the Austral University of Chile (No. 36/23).

Sample: People over 18 years of age (and up to 30 years of age) enrolled in the Physical Therapy program at the Austral University of Chile will be included. They must be physically inactive (perform less than 150 minutes/week of moderate physical activity and/or 75 minutes/week of vigorous physical activity) and without medical contraindications to perform physical activity. People who are taking medications that influence blood glucose or insulin levels and/or with anti-inflammatory effects will be excluded. The sample size calculation was performed considering the following parameters: a power of 95%, an alpha value of 0.05, a difference in pre- and post-intervention means of FGF21 of 50 pg/ml (100 vs 150 pg/ml), with a standard deviation for both groups of 50 pg/ml. With these data, the sample size is 16 participants, and considering a 20% drop-off, the final size is 20 participants, where recruitment will be by convenience and maintaining gender parity.

Variables: At the time of entering the study, the age years, and sex of the participants will be recorded. Anthropometric variables such as weight in kilograms and height in meters will be recorded using a scale (InBody® 270) and a height rod (SECA) respectively. From these measurements, the body mass index (BMI) will be calculated in kilograms/meters. For the calculations of the waist-hip ratio (WHR) and waist-height ratio (WHR), the waist circumference will be measured in centimeters using the navel area as a reference point. The hip circumference will be measured as the largest circumference obtained at the trochanteric femoral level. The levels of total and segmental muscle and fat mass will be measured using the InBody® 270 bioimpedance meter. The level of spontaneous physical activity will be measured using the International Physical Activity Questionnaire (IPAQ) in its short version. To induce elevations in blood lactate, an incremental load test will be applied on a cycle ergometer or stationary bicycle, in which the pedaling load will be increased by 30W every 3 minutes, starting from an initial load of 30W until reaching the point of fatigue. Before starting the test, participants will remain seated for 10 minutes, during which time heart rate, subjective sense of exertion (SSE) with the modified Borg Scale, blood pressure, pulse oximetry, and muscle (vastus lateralis of quadriceps) will be recorded at rest. In addition, a venous blood sample will be taken in a 2 ml tube with EDTA and another tube without anticoagulant for the subsequent plasma measurement of FGF21 with a specific ELISA kit for this (RayBio® catalog ELH-FGF21) and complementary biochemical tests (glycemia, insulinemia, total cholesterol, triglycerides, HDL, LDL, VLDL, non-HDL cholesterol, transaminases (GOT and GPT), creatinine, uric acid, urea and urea nitrogen). In addition, lactate measurement will be performed from a digital prick with a sterile lancet. For this, a specific reactive strip will be used, which will be measured with the AccuTrend Plus ® device. In parallel, the participant will be asked to bring a urine sample from the same day on an empty stomach for biochemical analysis (proteinuria, creatinuria, albuminuria, glucosuria). Once these measurements have been taken at rest, the incremental stress test will begin. Thus, on a cycle ergometer, each participant will begin the test with a pedaling cadence of 60-70 RPM at 30W load. Every 3 minutes this load will increase by 30W, always maintaining the same pedaling cadence. During the execution of the test, participants will always be supervised and guided by a professional physical therapist. Heart rate, pulse and muscle oximetry, and SSE will be assessed minute by minute, while blood pressure will be measured every 3 minutes. At the end of the test, the test execution time, the distance traveled in meters, heart rate, blood pressure, SSE, and final pulse and muscle oximetry will be recorded. The percentage of frequency reserve used during the test will be calculated with the Karvonen formula, which depends on the heart rates at rest and post-test. Fatigue at the end of the test will be understood as the fulfillment of one or more of the following criteria: use of heart rate reserve ≥ 90%, subjective feeling of effort ≥ 18/20 according to the original Borg scale, blood pressure ≥ 200/100 mg of Hg, the desire of the participant to finish the test (Figure 3).

Immediately after the test, a new venous blood sample will be taken in a 2 ml EDTA tube and another tube without anticoagulant. In addition, the post-exercise blood lactate concentration will be measured by finger prick using a specific reagent strip and with the AccuTrend Plus ® device. In addition, a post-exercise urine sample will be requested for the biochemical analysis previously described. Subsequently, the participant's vital signs will be monitored for 10 minutes after the test to ensure proper recovery.

It is reiterated that, as an assessment of potential confounding/intermediate variables, the following biochemical parameters will be measured from blood samples taken pre- and post-exercise: Total cholesterol, triglycerides, HDL, LDL, VLDL, non-HDL cholesterol, insulin, glucose, and transaminases (GOT, GPT), creatinine, uric acid, urea, and urea nitrogen. While, for urine samples, the levels of proteinuria, albuminuria, creatinuria, and glucose will be assessed.

Statistical analysis

Quantitative variables will be expressed as median and interquartile range, while qualitative variables will be described in terms of absolute frequencies. To calculate potential differences between pre-and post-stress test values, particularly lactate and FGF21, as well as transaminase levels and kidney function markers, the Wilcoxon test or Student t-test for related samples will be used, depending on how the data distribution behaves (normal or nonparametric). In addition, associations between lactate and FGF21 concentrations, both pre-and post-exercise, will be explored using the Spearman correlation index and bivariate regression models. In addition, other potential associations of interest will be explored using the Spearman correlation index. For all analyses, a p-value equal to or less than 0.05 will be considered statistically significant, using SPSS version 20 and GraphPad version 8 software.

02

Conditions studied

  • Physical Deconditioning

Keywords

  • Insulin
  • Metabolism
  • Exercise
03

In context

Lead sponsor

This is the only study on the registry with Sergio Martinez-Huenchullan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Physically inactive (less than 150 minutes of weekly moderate-intensity or less than 75 minutes of weekly vigorous physical activity.

Without medical contraindication to perform physical activity

Exclusion criteria

Exclusion Criteria:

  • Consumption of drugs with anti-inflammatory and/or hypoglycemic effects during the last two weeks.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Progressive exercise test

    The incremental effort test will be performed. Thus, on a cycle ergometer, each participant will begin the test with a pedaling cadence of 60-70 RPM at 30W load. Every 3 minutes, this load will increase by 30W, always maintaining the same pedaling cadence. Heart rate, blood pressure, rating of perceived effort, pulse oximetry and muscle oximetry will be monitored throughout the test.

    Behavioral: Exercise

Interventions

  • BehavioralExercise

    Progressive exercise testing on a cyclo ergometer

06

What researchers measure

Primary outcomes

  1. Glycemia

    Glucose in mg/dl

    Time frame: Up to 2 months

  2. Insulinemia

    Insulin in uUI/ml

    Time frame: Up to 2 months

Secondary outcomes

  1. Total cholesterol

    Total cholesterol in mg/dl

    Time frame: Up to 2 months

  2. HDL cholesterol

    HDL cholesterol in mg/dl

    Time frame: Up to 2 months

  3. LDL cholesterol

    LDL cholesterol in mg/dl

    Time frame: Up to 2 months

  4. VLDL cholesterol

    VLDL cholesterol in mg/dl

    Time frame: Up to 2 months

  5. Triglycerides

    Triglycerides in mg/dl

    Time frame: Up to 2 months

  6. GOT (transaminase)

    GOT in U/L

    Time frame: Up to 2 months

  7. GPT (transaminase)

    GPT in U/L

    Time frame: Up to 2 months

  8. Proteinuria

    Proteinuria in mg/dl

    Time frame: Up to 2 months

  9. Creatinine clearance

    Creatinine clearance in g/L

    Time frame: Up to 2 months

  10. Albuminuria

    Albuminuria in mg/L

    Time frame: Up to 2 months

  11. Glucosuria

    Glucosuria in mg/dl

    Time frame: Up to 2 months

07

Study locations

1 site
  • Universidad San Sebastián
    Valdivia, Los Rios 5090000, Chile
08

References and documents

Publications

  • Goodwin ML, Harris JE, Hernandez A, Gladden LB. Blood lactate measurements and analysis during exercise: a guide for clinicians. J Diabetes Sci Technol. 2007 Jul;1(4):558-69. doi: 10.1177/193229680700100414. PubMed 19885119 ↗
  • Garneau L, Parsons SA, Smith SR, Mulvihill EE, Sparks LM, Aguer C. Plasma Myokine Concentrations After Acute Exercise in Non-obese and Obese Sedentary Women. Front Physiol. 2020 Feb 18;11:18. doi: 10.3389/fphys.2020.00018. eCollection 2020. PubMed 32132925 ↗
  • Slusher AL, Whitehurst M, Zoeller RF, Mock JT, Maharaj M, Huang CJ. Attenuated fibroblast growth factor 21 response to acute aerobic exercise in obese individuals. Nutr Metab Cardiovasc Dis. 2015 Sep;25(9):839-845. doi: 10.1016/j.numecd.2015.06.002. Epub 2015 Jun 16. PubMed 26141939 ↗
  • Sabaratnam R, Pedersen AJT, Kristensen JM, Handberg A, Wojtaszewski JFP, Hojlund K. Intact regulation of muscle expression and circulating levels of myokines in response to exercise in patients with type 2 diabetes. Physiol Rep. 2018 Jun;6(12):e13723. doi: 10.14814/phy2.13723. PubMed 29924476 ↗
  • Ming AY, Yoo E, Vorontsov EN, Altamentova SM, Kilkenny DM, Rocheleau JV. Dynamics and Distribution of Klothobeta (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J Biol Chem. 2012 Jun 8;287(24):19997-20006. doi: 10.1074/jbc.M111.325670. Epub 2012 Apr 20. PubMed 22523080 ↗
  • Fisher FM, Maratos-Flier E. Understanding the Physiology of FGF21. Annu Rev Physiol. 2016;78:223-41. doi: 10.1146/annurev-physiol-021115-105339. Epub 2015 Nov 19. PubMed 26654352 ↗
  • Laurens C, Bergouignan A, Moro C. Exercise-Released Myokines in the Control of Energy Metabolism. Front Physiol. 2020 Feb 13;11:91. doi: 10.3389/fphys.2020.00091. eCollection 2020. PubMed 32116795 ↗
  • Quinn A, Doody C, O'Shea D. The effect of a physical activity education programme on physical activity, fitness, quality of life and attitudes to exercise in obese females. J Sci Med Sport. 2008 Sep;11(5):469-72. doi: 10.1016/j.jsams.2007.07.011. Epub 2007 Sep 14. PubMed 17869182 ↗
  • Pedersen BK. The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk. J Physiol. 2009 Dec 1;587(Pt 23):5559-68. doi: 10.1113/jphysiol.2009.179515. Epub 2009 Sep 14. PubMed 19752112 ↗
  • Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018 Jan 2;71(1):69-84. doi: 10.1016/j.jacc.2017.11.011. PubMed 29301630 ↗

Study documents

  • Study protocol · Nov 4, 2024
  • Informed consent form · Nov 4, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — All IPD collected during the trial

Supporting information: Study protocol, Sap, Icf, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06680713
Lead sponsor
Sergio Martinez-Huenchullan
Collaborators
Universidad Austral de Chile
Responsible party
Sergio Martinez-Huenchullan (Associate Professor, Universidad San Sebastián) — Sponsor-investigator
First posted
Nov 8, 2024
Start date
Jun 18, 2024
Primary completion
Jul 17, 2024
Completion
Jul 31, 2024
Last update
Nov 8, 2024

Study contacts

Sergio F Martinez-Huenchullan, PhD
principal investigator · Universidad San Sebastián

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion